Beta blocker and lisinopril to protect the heart in AML
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests whether a blood-pressure medicine plan (a beta blocker plus lisinopril) can protect the heart in people newly diagnosed with acute myeloid leukemia (AML) who are starting anthracycline chemotherapy. It looks at heart safety by requiring a good heart scan before treatment and careful medication eligibility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and newly diagnosed with AML
- Plan to start AML induction treatment that includes an anthracycline (you may start if it hasn’t included one yet)
- Be able to swallow and follow the beta blocker and lisinopril schedule during the study
- Have a heart ultrasound (echocardiogram) showing good heart pumping (ejection fraction 50% or higher)
- Have acceptable blood tests for liver and kidney function (doctor will check labs before enrollment)
- Not be taking a beta blocker or ACE inhibitor already at screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial adds an experimental drug called bleximenib to the usual chemotherapy for people newly diagnosed with AML who have certain genetic changes (NPM1 or KMT2A). The goal is to see if adding this drug helps the treatment work better.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This trial tests a new drug called Lonitoclax combined with azacitidine for people with AML that has come back or not responded to prior treatment. The study will see if the combination is safe and can help control the leukemia.
This study tests a new drug called BL-M11D1 combined with standard chemotherapy (cytarabine + daunorubicin) or a targeted therapy (venetoclax + azacitidine) for people with newly diagnosed acute myeloid leukemia (AML). It aims to see if this combination is safe and effective.
This study tests three different chemotherapy regimens (LDA, LHAA, and DA) in adults aged 18–65 with newly diagnosed acute myeloid leukemia (AML, a blood cancer). The goal is to find which approach works best and is safest for patients fit enough for intensive treatment.
This trial studies whether combining two medicines—midostaurin and gemtuzumab (with standard chemotherapy)—can improve outcomes for newly diagnosed acute myeloid leukemia (AML). It is testing a first-line treatment plan tailored to specific genetic changes in the leukemia.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.